Results. - Sixteen patients were included (9 women and 7 men). They had recurrent anterior uveitis (n=10), recurrent scleritis (n=5) and intermediate uveitis. Opthalmological involvement was neither severe nor complicated. All patients combined, the annual relapse ratio (ARR) decreased from 1.8 (0.8-3.5) to 0.3 (0-1.6), (P=0.06). Colchicine was considered effective in three of 10 analyzable patients. In only one patient, treatment was stopped for adverse effects after six weeks. Conclusion. - In view of the interesting benefit-risk ratio of colchicine, it seems appropriate to focus on this molecule in non-granulomatous anterior uveitis and non-severe recurrent scleritis. © 2022 Socie acute accent te acute accent Nationale Franc , aise de Me acute accent decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

Introduction. - Colchicine is a narrow therapeutic margin drug that does not have the adverse effects of corticosteroids and immunosuppressants. Its use in non-severe ocular inflammatory disease excluding Behcet's disease has not been studied. Methods. - We included patients seen in the internal medicine department of Dijon University Hospital consecutively between September 2020 and September 2021 if they had received colchicine during their pathology. Patients with suspected Behc , et's disease were excluded. Treatment efficacy was studied in patients with at least one year of disease progression who had received more than one year of colchicine. Successful treatment was defined as a 50 % reduction in the number of annual relapses on colchicine. Results. - Sixteen patients were included (9 women and 7 men). They had recurrent anterior uveitis (n =10), recurrent scleritis (n = 5) and intermediate uveitis. Opthalmological involvement was neither severe nor complicated. All patients combined, the annual relapse ratio (ARR) decreased from 1.8 (0.8-3.5) to 0.3 (0-1.6), (P= 0.06). Colchicine was considered effective in three of 10 analyzable patients. In only one patient, treatment was stopped for adverse effects after six weeks. Conclusion. - In view of the interesting benefit-risk ratio of colchicine, it seems appropriate to focus on this molecule in non-granulomatous anterior uveitis and non-severe recurrent scleritis. (c) 2022 Socie acute accent te acute accent Nationale Franc , aise de Me acute accent decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

Automated summary

This study aimed to explore the use of colchicine in non-severe ocular inflammatory disease. The results of the study showed that colchicine was considered effective in some analyzable patients. Therefore, colchicine may be a treatment option for non-granulomatous anterior uveitis and non-severe recurrent scleritis.